C4X Discovery receives $11m from AstraZeneca for COPD drug progress
3rd Jan 2024 07:12
(Sharecast News) - C4X Discovery, the AIM-listed drug discovery company, has received a "milestone payment" of $11m from biopharma giant AstraZeneca as part of the progress of its NRF2 Activator programme, causing shares to jump by nearly a half on Wednesday.
Read moreC4X Discovery launches new precision medicine platform
22nd Feb 2023 12:43
(Sharecast News) - C4X Discovery launched a new precision medicine platform called 'PatientSeek' on Wednesday, after a successful research collaboration with the Garvan Institute of Medical Research.
Read moreC4X makes positive progress with potential cancer programme
19th Jan 2023 16:14
(Sharecast News) - C4X Discovery updated on its 'MALT-1' inhibitor programme on Thursday, explaining that the overexpression or over-activation of MALT-1 has been observed in a range of lymphomas and leukemias such as MALT lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukaemia.
Read moreC4X promotes Nick Ray to chief scientific officer
10th Jan 2023 15:38
(Sharecast News) - Drug discovery company C4X announced the appointment of Nick Ray as its chief scientific officer on Tuesday, with immediate effect.
Read moreC4X Discovery signs up-to-$402m deal with AstraZeneca
28th Nov 2022 14:02
(Sharecast News) - Drug discovery specialist C4X has signed an exclusive worldwide licensing agreement with AstraZeneca worth up to $402m, it announced on Monday, for its 'NRF2 Activator' programme.
Read moreC4X raises £5.7m to support development activities
11th Aug 2022 15:39
(Sharecast News) - Drug discovery company C4X announced a proposed placing to raise up to £5.7m on Thursday, to support its corporate development and ongoing commercial activities.
Read moreC4X Discovery appoints Cathy Tralau-Stewart as new science chief
21st Dec 2021 12:57
(Sharecast News) - Drug discovery company C4X announced the appointment of Catherine Tralau-Stewart as its new chief scientific officer on Tuesday, effective from 4 January.
Read moreC4X Discovery signs exclusive licensing deal with Sanofi
12th Apr 2021 08:41
(Sharecast News) - C4X Discovery has signed an exclusive worldwide licensing agreement with Sanofi worth up to €414m (£357.84m), it announced on Monday, for its oral preclinical IL-17A inhibitor programme.
Read moreC4X Discovery CEO to be interim chair of UK Vaccine Taskforce
8th Dec 2020 12:26
(Sharecast News) - Drug discovery company C4X Discovery confirmed on Tuesday that its chief executive officer Clive Dix has stepped into the role of interim chair of the UK Vaccine Taskforce.
Read moreC4X losses widen as its revenue drops to nil
7th Jan 2020 09:59
(Sharecast News) - Drug discovery company C4X Discovery Holdings announced a fall in revenue to nil in its full-year results on Tuesday, from £7.06m in 2018, which the board said as driven entirely by the Indivior licensing agreement in that year.
Read moreC4X makes solid progress across portfolio of programmes
1st Oct 2019 10:15
(Sharecast News) - Drug discovery company C4X Discovery Holdings announced progress across a number of key programmes in line with its strategy on Tuesday, reporting that it was continuing to progress its strategy to deliver programmes for out-licensing its NRF-2 activator, IL-17 inhibitor and LifeArc collaboration.
Read moreC4X upbeat as its molecule progresses with Indivior
27th Sep 2019 15:39
(Sharecast News) - Drug discovery company C4X Discovery Holdings noted an announcement on Friday that the National Institutes of Health (NIH) in the United States has granted Indivior's application titled "Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder'.
Read moreE-Therapeutics and C4X upbeat on Parkinson's collaboration
6th Dec 2018 16:04
(Sharecast News) - Network-driven drug discovery company e-Therapeutics and C4X Discovery Holdings updated the market on their collaboration on Thursday, to identify novel intervention strategies for the potential treatment of Parkinson's Disease (PD).
Read moreC4X enters drug discovery AI deal with GTN
29th Nov 2018 12:21
(Sharecast News) - Drug discovery company C4X Discovery Holdings has entered into a partnership with GTN, a new player in the field of drug discovery artificial intelligence, initially focussing on identifying potential small molecule hits against a high-value neurodegeneration target, it announced on Thursday.
Read moreC4X Discovery Holdings focuses on early licensing deals to drive revenue
6th Jan 2017 08:13
(ShareCast News) - Drug discovery company C4X Discovery Holdings is focusing on early licensing deals to drive revenue as it bids to become the world's most productive drug discovery engine. The AIM-listed company said it shifted focus on generating a high value pre-clinical asset portfolio that wil
Read more